These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25127887)

  • 1. A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients (IVIST01-trial): study protocol for a randomized controlled trial.
    Ahlenstiel-Grunow T; Koch A; Großhennig A; Frömke C; Sester M; Sester U; Schröder C; Pape L
    Trials; 2014 Aug; 15():324. PubMed ID: 25127887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial.
    Ahlenstiel-Grunow T; Liu X; Schild R; Oh J; Taylan C; Weber LT; Staude H; Verboom M; Schröder C; Sabau R; Großhennig A; Pape L
    J Am Soc Nephrol; 2021 Feb; 32(2):502-516. PubMed ID: 33323473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ways to monitor immunosuppression in pediatric kidney transplant recipients-underlying concepts and emerging data.
    Ahlenstiel-Grunow T; Pape L
    Mol Cell Pediatr; 2021 Jul; 8(1):8. PubMed ID: 34309698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation.
    Ahlenstiel-Grunow T; Pape L
    Pediatr Nephrol; 2020 Mar; 35(3):375-382. PubMed ID: 30539254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-specific T cells in pediatric renal transplantation.
    Ahlenstiel-Grunow T; Pape L
    Pediatr Nephrol; 2021 Apr; 36(4):789-796. PubMed ID: 32221706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load-guided immunosuppression after lung transplantation (VIGILung)-study protocol for a randomized controlled trial.
    Gottlieb J; Reuss A; Mayer K; Weide K; Schade-Brittinger C; Hoyer S; Jaksch P
    Trials; 2021 Jan; 22(1):48. PubMed ID: 33430927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
    Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
    Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M; Arias M; Campistol JM; Navarro D; Gómez-Huertas E; Gómez-Márquez G; Díaz JM; Hernández D; Bernal-Blanco G; Cofan F; Jimeno L; Franco-Esteve A; González E; Moreso FJ; Gómez-Alamillo C; Mendiluce A; Luna-Huerta E; Aguado JM;
    Transpl Int; 2015 Sep; 28(9):1042-54. PubMed ID: 25864986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
    Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
    Trials; 2014 Dec; 15():489. PubMed ID: 25494823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the effects of CMV on long-term transplant outcome.
    Baron C; Forconi C; Lebranchu Y
    Curr Opin Organ Transplant; 2010 Aug; 15(4):492-8. PubMed ID: 20631617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Nashan B; Thaiss F
    Trials; 2016 Feb; 17():92. PubMed ID: 26888217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
    Andrei G; Van Loon E; Lerut E; Victoor J; Meijers B; Bammens B; Sprangers B; Gillemot S; Fiten P; Opdenakker G; Lagrou K; Kuypers D; Snoeck R; Naesens M
    Antiviral Res; 2019 Aug; 168():203-209. PubMed ID: 31212020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
    Höcker B; Tönshoff B
    Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.